Upadacitinib achieved significant scalp hair regrowth, with roughly half of severe alopecia areata patients reaching 80 percent or more scalp coverage at week 24 across two phase 3 clinical trials. The medication demonstrated efficacy in both adolescents and adults, alongside notable improvements in eyelashes, eyebrows, and overall quality of life.
For patients dealing with severe alopecia areata, the journey can have a substantial effect on quality of life. This condition is an autoimmune disorder that leads to non-scarring hair loss on the scalp and other areas of the body, potentially advancing to complete hair loss across the entire body in certain instances. Recent clinical data presented at the American Academy of Dermatology meeting highlights a therapeutic avenue for individuals.
In Plain English: The Clinical Takeaway
- What was tested: Upadacitinib.
- The core finding: Roughly half of trial participants with severe hair loss achieved 80% or more scalp coverage after 24 weeks.
- Beyond the scalp: Patients also experienced measurable regrowth in eyebrows and eyelashes, alongside improvements in quality-of-life measures.
Phase III Trial Outcomes and Dosing Efficacy
Data from the UP-AA Phase III clinical program, specifically Study 1 and Study 2 presented by researchers including M. Gooderham, evaluated the safety and efficacy of upadacitinib across both adolescent and adult cohorts. Investigators measured outcomes using the Severity of Alopecia Tool (SALT), where a score of 20 or less indicates 80 percent or greater scalp hair coverage.
Among adolescents, response rates for achieving a SALT score of 20 or lower reached 56.0% and 56.5% with the 15 mg dose in Study 1 and Study 2 respectively. Higher efficacy emerged in the 30 mg cohort, where response rates climbed to 84.6% and 76.2%. Adult participants taking the 15 mg dose recorded response rates of 44.1% and 43.6%, while the 30 mg dose yielded 51.8% and 52.6% response rates. By comparison, placebo groups across both demographics showed low response rates, registering 0% in Study 1 and 10.0% in Study 2 for adolescents, and 1.6% and 3.0% for adults.
| Demographic & Dose | Study 1 Response Rate (%) | Study 2 Response Rate (%) |
|---|---|---|
| Adolescents (15 mg) | 56.0% | 56.5% |
| Adolescents (30 mg) | 84.6% | 76.2% |
| Adults (15 mg) | 44.1% | 43.6% |
| Adults (30 mg) | 51.8% | 52.6% |
| Placebo (Adult Control) | 1.6% | 3.0% |
Mechanism of Action and Immunological Targets
Alopecia areata is an autoimmune disease. Clinical investigators noted that safety findings were generally consistent with the known profile of upadacitinib, with serious treatment-emergent adverse events reported in 3.0% or fewer adult participants and none among adolescents.
References
- Gooderham M, et al. Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program. Abstract 76957. AAD Annual Meeting.
